Clinical trials: Post-ERCP Acute Pancreatitis
Pancreatitis, Acute
COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- NCT02964403
- Testing
- Cox-2, Indomethacin
- Volunteers
- 2,700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Post-ERCP Acute Pancreatitis
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from < 2% up to 40%.
- Trial name
- PEP-PREPARE (NCT04770857)
- Testing
- Visual analogue scale
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- Nicola Frei
Post-ERCP Acute Pancreatitis
Rectal Indomethacin vs Intravenous Ketorolac
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP.
- Trial name
- NCT05664074
- Testing
- Rectal indomethacin, IV ketorolac
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- David Vitale MD
Cholangitis, Post-ERCP Acute Pancreatitis
Optimal Placement Duration of Pancreatic Duct Stent
A randomized controlled trial to determine the optimal placement duration of pancreatic duct stents (PDS) inserted during ERCP: 2 vs 4 weeks
- Conditions
- Cholangitis, Post-ERCP Acute Pancreatitis, Stent Dislodgement
- Trial name
- NCT04691674
- Testing
- Endoscopy
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- DongGuk University
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- Indomethacin (NCT02002650)
- Testing
- Pre-ERCP rectal Indomethacin, Post-operational Rectal Indomethacin
- Where
- 6 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis
Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
This research is being done to see if using a combination of rectal indomethacin and epinephrine spray during endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
- Trial name
- INDIEH (NCT02116309)
- Testing
- Rectal Indomethacin, Epinephrine
- Where
- 4 sites in United States, India
- Volunteers
- 948 people
- Sponsor
- Johns Hopkins University
Post-ERCP Acute Pancreatitis, Epinephrine
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication with high costs, significant morbidity and even mortality.
- Trial name
- NCT03756116
- Testing
- Epinephrine sprayed on the papilla, Saline sprayed on the papilla
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Post-ERCP Acute Pancreatitis
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
The aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ERCP and how it correlates with their quality of life and productivity.
- Trial name
- PAN-PROMISE (NCT05310409)
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Post-ERCP Acute Pancreatitis
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). The incidence of post-ERCP pancreatitis (PEP) is estimated to be 10% to 15% in high-risk patients.
- Trial name
- NCT04145336
- Testing
- 5cm 5-Fr PDS, 7cm 5-Fr PDS, Indomethacin
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
This research is being done to see if using oral tacrolimus before endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
- Trial name
- INTRO (NCT05252754)
- Testing
- Tacrolimus capsule, Rectal Indomethacin
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 4,874 people
- Sponsor
- Johns Hopkins University
Post-ERCP Acute Pancreatitis
Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis
ERCP (endoscopic retrograde cholangiopancreatography) has been largely demonstrated to be effective in multiple bilio-pancreatic indications.
- Trial name
- NCT01855841
- Testing
- Hemin
- Where
- 6 sites in Belgium, Taiwan
- Volunteers
- 284 people
- Sponsor
- Erasme University Hospital
Post-ERCP Acute Pancreatitis
Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis
The purpose of this study is to compare the incidence of post-ERCP pancreatitis (PEP) in chronic pancreatitis (CP) patients to that in biliary disease patients, to determine whether CP patients in early clinical stage have a…
- Trial name
- NCT02781987
- Testing
- chronic pancreatitis
- Volunteers
- 2,028 people
- Sponsor
- Changhai Hospital
Acute Pancreatitis (AP), Gallstone Pancreatitis
Pentoxifylline Treatment in Acute Pancreatitis (AP)
The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.
- Conditions
- Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis
- Trial name
- AP (NCT02487225)
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Mayo Clinic
Post-ERCP Acute Pancreatitis
Statins and Post-ERCP Acute Pancreatitis (Stark Project)
Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure.
- Trial name
- Stark (NCT06367322)
- Testing
- Statin
- Where
- 2 sites in Spain
- Volunteers
- 1,016 people
- Sponsor
- Hospital General Universitario de Alicante
Post-ERCP Acute Pancreatitis
Post-ERCP Pancreatitis Prevention by Stent Insertion
The presented study is designed to analyze the efficacy of pancreatic stent insertion in patients undergoing ERCP with accidental cannulation of the pancreatic duct.
- Trial name
- PEPSI (NCT01673763)
- Testing
- Stent insertion into the main pancreatic duct
- Where
- 4 sites in Belgium, Germany and 2 more
- Volunteers
- 169 people
- Sponsor
- Technical University of Munich
Post-ERCP Acute Pancreatitis
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
Post endoscopic pancreatitis (PEP) has different initial immunologic response to primary injury compared to acute pancreatitis of other etiology (non-PEP AP).
- Trial name
- NCT02602574
- Testing
- heparinized peripheral venous blood and urine sample.
- Where
- Croatia
- Volunteers
- 66 people
- Sponsor
- University Hospital Rijeka
Post ERCP Pancreatitis, Acute Pancreatitis (AP)
Cold Water Papillary Irrigation Plus Rectal NSAIDs vs Rectal NSAIDs Alone for Post-ERCP Pancreatitis (COLD)
Post-ERCP pancreatitis is the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) are the current standard prophylaxis.
- Trial name
- COLDHUVN (NCT07885852)
- Testing
- Cold water irrigation of the papilla, Rectal NSAID (diclofenac 100 mg)
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- University Hospital Virgen de las Nieves
Acute Pancreatitis
Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Acute pancreatitis is the most frequent (5-10%) and severe complication after endoscopic retrograde cholangiopancreatography (ERCP), that could require of surgical intervention and lead to death.
- Trial name
- crepsmt1 (NCT01060826)
- Testing
- fisiologic serum, somatostatin, intravenous bolus, somatostatin
- Where
- 2 sites in Spain
- Volunteers
- 510 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Pancreatitis, Acute, Gastrointestinal Disease
Oral Resveratrol to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- NCT02947932
- Testing
- Resveratrol, Indomethacin
- Volunteers
- 2,700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Pancreatitis, Acute, ERCP
Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)
This is a prospective, observational (non-interventional), multicenter study that will look at how often inflammation of the pancreas (called post-ERCP pancreatitis, or PEP) occurs after an endoscopic procedure known as ERCP.
- Conditions
- Pancreatitis, Acute, ERCP, Prophylaxis
- Trial name
- PEP-PROMIS (NCT07244432)
- Where
- 13 sites in Czechia, Slovakia
- Volunteers
- 1,135 people
- Sponsor
- Branislav Kuncak